

GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock Code 股份代號: 6998)

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Genor Biopharma Holdings Limited (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form will be disseminated to its shareholders (the "Shareholders") electronically and only send Corporate Communications in printed form to the Shareholders upon request.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.genorbio.com and the HKExnews website at www.hkexnews.hk in place of printed copies. The Company will not send a notice of publication of the Corporate Communications to the Shareholders. The Shareholders are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Corporate Communications by themselves. The Company will send the Actionable Corporate Communications (Note) to its registered shareholders individually in electronic form by email.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications^(Note), the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send you the Actionable Corporate Communications $^{(Note)}$ in printed form together with a request form for soliciting your functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form to the Share Registrar or send an email to genorbio.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Details of the arrangements (i) for dissemination of Corporate Communications and (ii) for requesting printed copy of Corporate Communications are also published under the "Corporate Communications Arrangement" section in the Company's website (www.genorbio.com). Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Genor Biopharma Holdings Limited
Dr. Guo Feng

Executive Director, Chief Executive Officer and Chairman

31 July 2024

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07A 條,嘉和生物藥業(開曼)控股有限公司(「**公司**」) 謹此通知 閣下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,即公司發佈或將要發佈以供其任何證券的持有人參照或採取行動的任何文件,包括但不限於(a) 董事報告、年度帳目以及核數師報告副本以及(如適用)財務摘要報告; (b) 中期報告及其中期報告摘要(如適用); (c) 會議通知; (d) 上市文件; (e) 通函和 (f) 委任表格將以電子方式向其股東(「**股東**」)發佈,並僅應股東要求向其發送公司通訊之印刷版。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.genorbio.com和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。本公司不會向股東發送刊發公司通訊之通知。務請股東主動監控可在網站獲得之所有未來公司通訊,並自行查閱公司通訊。公司將以電子通訊方式(通過電子郵件)向登記股東個別地發送可供採取行動的公司通訊(Milla)。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(解註),公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式向 閣下發送可供採取行動的公司通訊(Miti),連同一份索取 閣下有效電子郵件地址的表格,以便將來以電子方式發送可供採取行動的公司通訊。

若 閣下希望收取公司通訊之印刷版,請填妥回條並交回股份過戶處,或發送電子郵件至 genorbio.ecom@computershare.com.hk,並註明 閣下的姓名、 地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

有關(i) 以電子方式發佈公司通訊及(ii) 索取公司通訊印刷版的安排詳情亦登載於公司網站 www.genorbio.com 的「公司通訊之安排」部分。如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)期間致電股份過戶處(852)2862 8688 查詢。

承董事會命 **嘉和生物藥業(開曼)控股有限公司** 執行董事、行政總裁兼主席 **郭峰博士**

二零二四年七月三十一日

REPLY FORM 回條			
putershare Hong Kong Investor Services Limited "Share Registrar") Floor, Hopewell Centre Queen's Road East, Wan Chai, Hong Kong	致:	香港中央證券登記有限公司 (「股份過戶處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓	
se ONLY ONE of the options below) 項中只選擇其中一項)			
1: Provide email address for receipt of future	e Actionable Corno	rate	Personalized QR Code 專屬二維碼
	-		
personalized QR code		·	
: 掃瞄專屬二維碼提供電子郵件地址,以接	收公司通過電子方式	式	
發佈的可供採取行動的未來公司通訊 <i>隨註3</i>)		
Returning this Reply Form is NOT requ 如選擇了選項 1 · 無須 交回本回條。	uired if Option 1 is	chosen.	
I/we hereby provide my/our email address in writing for	receipt of future Actional	ble Corporate Communications (No	ote 3) of the following listed
company (the "Company") via electronic dissemination	receipt of facult (facult	or corporate communications	or the following libred
本人/吾等現以書面提供本人/吾等的電子郵件地址‧以確	全保收到以下上市公司(「	「公司」)通過電子方式發佈的可	供採取行動的未來公司通訊 ^{<i>們註:</i>}
ecurities holder(s) 證券持有人姓名:			
		8	
ress 電郵地址: ^(Note 3 / 附註3)	新加工物来来(用 豆		
	"Share Registrar") Floor, Hopewell Centre Queen's Road East, Wan Chai, Hong Kong se ONLY ONE of the options below) 項中只選擇其中一項) 1: Provide email address for receipt of future Communications(Note 3) of the Company virus personalized OR code : 掃瞄專屬二維碼提供電子郵件地址・以接發佈的可供採取行動的未來公司通訊(Mitt 3) Returning this Reply Form is NOT reque 如選擇了選項 1・無須交回本回條。 I/we hereby provide my/our email address in writing for company (the "Company") via electronic dissemination 本人/吾等現以書面提供本人/吾等的電子郵件地址・以確	"Share Registrar") Floor, Hopewell Centre Queen's Road East, Wan Chai, Hong Kong se ONLY ONE of the options below) 項中只選擇其中一項) 1: Provide email address for receipt of future Actionable Corpor Communications (Note 3) of the Company via electronic disseming personalized QR code : 掃瞄專屬三維碼提供電子郵件地址,以接收公司通過電子方式發佈的可供採取行動的未來公司通訊 (MEL 3) Returning this Reply Form is NOT required if Option 1 is 如選擇了選項 1,無須交回本回條。 I/we hereby provide my/our email address in writing for receipt of future Actional company (the "Company") via electronic dissemination 本人/吾等現以書面提供本人/吾等的電子郵件地址,以確保收到以下上市公司(ecurities holder(s) 證券持有人姓名: Name of the listed comp Genor Biopharma Eagle	"Share Registrar") (「股份過戶處」) Floor, Hopewell Centre Queen's Road East, Wan Chai, Hong Kong 合和中心 17M 樓 Se ONLY ONE of the options below) 項中只選擇其中一項) 1: Provide email address for receipt of future Actionable Corporate Communications(Note 3) of the Company via electronic dissemination by scanning personalized QR code : 掃瞄專屬三維碼提供電子郵件地址・以接收公司通過電子方式 發佈的可供採取行動的未來公司通訊(Mitt 3) Returning this Reply Form is NOT required if Option 1 is chosen. 如選擇了選項 1・無須交回本回條。 I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications(Note Company) (the "Company") via electronic dissemination 本人/吾等現以書面提供本人/吾等的電子郵件地址・以確保收到以下上市公司(「公司」)通過電子方式發佈的可能

Notes 附註: 1. Please co Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid. 請清楚填妥 閣下之所有資料。如屬聯名股東.則本回條須由所有聯名股東聯合簽署.方為有效。

1. Please complete all your actions (seeins is your shows we may not making steeins it your shows when the process of the pr

Contact number:

聯絡電話號碼:

- * Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report;(b) the interim report and, where applicable, its summary interim report; and, where applicable, its summary financial report; and, where applicable, its summary financial report; and, where applicable, its summary financial report; and, where applicable, its summary interim report; and the difference of the company of the auditors' report and accounts together with a copy of the auditors' report and, where applicable, its summary financial report; and accounts together with a copy of the auditors' report and, where applicable, its summary financial report; and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts together with a copy of the auditors' report and accounts to a copy of the auditors' report and accounts to a copy of the auditors' report and accounts to a copy of the auditors' report and accounts to a copy of the auditors' report and accoun

directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report,(b) the interim report and, where applicable, its summary interim report;(c) a notice of meeting;(d) a listing document;(e) a circular and (f) a proxy form.
除非另看註明·公司雖訊乃指公司已發出或將予發出以供其任何證券的特有人參照或採取行動的任何文件·其中包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及(如適用)其財務總要報告;(b) 中期報告及 (如適用)其中期德要報告;(c) 曹建邈告;(d) 上市文件;(e) 題曲和ff) 代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

Signature(s): (Note 1) 簽名: (附註 1)

- (i)
- 個人資料營明
 "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 本營明中所指的「個人資料,與香港法例第 486 章 【個人資料(私膳)條例》(「《私膳》條例》)(「《私膳》條例》),中「個人資料」的遊養相同。
 "Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

 國下於本回條所提供的個人資料將用於包括但不限於分類除公司以電子方式發布公司通訊及就 阁下持有的公司證券有關的其他事宜上與 阁下聯絡。阁下是自願向本公司提供個人資料。若阁下未能提供足夠資料。公司可能抵法遗理阁下在本回修上所述的指示及必要求。
 "Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
 公司可就任何所說則的用途或在法例规定的情况下。將、阁下的個人資料披露或轉移給公司的附屬公司、股份過戶處。及/或其他公司或團體。並將在適當期間保留該每個人資料作核實及紀錄用途。
 You have the right to request access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at Privacy Officer ecomputershare, comb. k.
- PrivacyOfficer@computershare.com.hk. 間下有權程達(私膳稼例)的條文查閱及/或修改 間下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處(地址為香港灣仔皇后大道東 183 號合和中心 17M 樓)向香港隱私主 任提出:或發送電郵至 <u>PrivacyOfficer@computershare.com.hk</u>。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

Date:

日期:

閣下寄回此回條時・請將郵寄標籤剪貼於信封上。 如在本港投寄・ 閣下無需支付郵費或貼上郵票。